Petros Pharmaceuticals' subsidiary, Metuchen, failed to pay a $7.2 million installment due on October 1, 2024, leading to all obligations becoming immediately due, with interest accruing at 9% per annum; the company accepted a proposal to satisfy $2 million of the debt with collateral.